Sign up to save your podcasts
Or
Share Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
Long-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.
View all episodes
By TheBrief.HealthLong-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.